Management Team
Location:Home > About us > Management Team

Kanyin E. Zhang, Ph.D., CEO and Cofounder

    Dr. Kanyin E. Zhang has more than 20 years of experience in drug discovery and development from both US and China.  Prior to Tarrex, Kanyin was a founding member of Argusina Biosciences, a drug discovery startup founded by Morningside Group and served as the general manager at its Shanghai R&D center.  Prior to returning to China, he worked at several US pharmaceutical and biotech companies for over a decade, including Merck, Agouron/Pfizer, and GNF (Genomics Institute of the Novartis Research Foundation) from research scientist to research director.  Kanyin received his Ph.D. degree from the School of Pharmacy at the University of Washington, Seattle. 

Kanyin also serves as a Board of Director of Aranda Pharma Ltd.

 


Xiaokun Zhang, Ph.D., Cofounder and Chief ScientificAdvisor

     Dr. Xiao-kun Zhang is the Dean of School of Pharmaceutical Sciences at the Xiamen University and Professor at the Sanford-Burnham Medical Research Institute, California.  He is among the first group of recipients of the China 1000 talent program. Throughout his career, he has devoted his research in the chemopreventive and therapeutic effects of nuclear receptors. He discovered a new vitamin A signaling pathway through nuclear receptor RXR protein complexes. As a result, Targretin, a small molecule ligand that activates RXRα,was identified and approved by the FDA for treating Cutaneous T-Cell Lymphoma.  Subsequent research by his team has led to the discovery of truncated RXRα (tRXRα) as a novel target for cancer therapy and TX803 that targets this oncoprotein.  Xiaokun received his Ph.D. degree from the University of Vermont in 1989.  He is a co-inventor of 9 US and 7 Chinese patents and co-author of 120 peer-reviewed publications.